Intellia Therapeutics, Inc.
NTLA
$11.91
$0.080.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.58% | 45.04% | 16.92% | 33.52% | 14.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.58% | 45.04% | 16.92% | 33.52% | 14.99% |
| Cost of Revenue | -23.75% | -20.91% | -14.98% | -10.77% | -4.75% |
| Gross Profit | 29.06% | 28.99% | 20.06% | 15.70% | 7.08% |
| SG&A Expenses | 10.95% | -7.39% | -11.93% | 1.22% | 11.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.50% | -17.02% | -14.10% | -7.67% | -0.90% |
| Operating Income | 17.29% | 22.24% | 17.46% | 10.97% | 2.29% |
| Income Before Tax | 16.71% | 24.97% | 20.49% | 14.64% | 5.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.71% | 24.97% | 20.49% | 14.64% | 5.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.71% | 24.97% | 20.49% | 14.64% | 5.62% |
| EBIT | 17.29% | 22.24% | 17.46% | 10.97% | 2.29% |
| EBITDA | 17.43% | 22.52% | 17.70% | 11.14% | 2.39% |
| EPS Basic | 28.42% | 32.42% | 27.11% | 21.66% | 14.42% |
| Normalized Basic EPS | 27.47% | 28.32% | 22.30% | 17.16% | 11.24% |
| EPS Diluted | 28.42% | 32.42% | 27.11% | 21.66% | 14.42% |
| Normalized Diluted EPS | 27.47% | 28.32% | 22.30% | 17.16% | 11.24% |
| Average Basic Shares Outstanding | 16.58% | 11.16% | 9.61% | 9.20% | 10.36% |
| Average Diluted Shares Outstanding | 16.58% | 11.16% | 9.61% | 9.20% | 10.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |